Article
Biology
Satoi Nagasawa, Yuta Kuze, Ichiro Maeda, Yasuyuki Kojima, Ai Motoyoshi, Tatsuya Onishi, Tsuguo Iwatani, Takamichi Yokoe, Junki Koike, Motohiro Chosokabe, Manabu Kubota, Hibiki Seino, Ayako Suzuki, Masahide Seki, Katsuya Tsuchihara, Eisuke Inoue, Koichiro Tsugawa, Tomohiko Ohta, Yutaka Suzuki
Summary: The study conducted a multi-omic analysis of ductal carcinoma in situ (DCIS) and identified age, gene amplification, and gene mutation as possible indicators of relapse. The results revealed heterogeneous cell populations in DCIS, providing predictive markers for classifying and optimizing treatment.
COMMUNICATIONS BIOLOGY
(2021)
Article
Oncology
Yufei Zeng, Weiqi Gao, Xiaosong Chen, Kunwei Shen
Summary: Patients with invasive ductal carcinoma (IDC) accompanied by ductal carcinoma in situ (DCIS) have a lower 21-gene recurrence score (RS) possibly due to lower expression of proliferation and invasion genes. The proportion and grade of DCIS independently influence the 21-gene RS in IDC/DCIS patients. Further evaluation is needed to determine the impact of the DCIS component in IDC on prognosis due to the relatively short follow-up period and low recurrence rate.
BRITISH JOURNAL OF CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zengjie Wu, Qing Lin, Haibo Wang, Guanqun Wang, Guangming Fu, Tiantian Bian
Summary: The study developed a radiomics nomogram based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to accurately differentiate between ductal carcinoma in situ with microinvasion (DCISM) and pure ductal carcinoma in situ (DCIS) breast cancer. The radiomics signature and nomogram model showed better performance in calibration and validation compared to the clinical factor model, indicating good potential for clinical utility.
ACADEMIC RADIOLOGY
(2023)
Article
Oncology
Leslie R. Lamb, Sarah Mercaldo, Tawakalitu O. Oseni, Manisha Bahl
Summary: In a study of nearly 550 women with DCIS undergoing BCS, 31.6% required at least one reexcision. Factors associated with reexcision included younger age, African-American race, ultrasound biopsy modality, and earlier year of surgery. Pathological features of DCIS were not found to be associated with the risk of reexcision.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Jiao Zhang, Hui Lin, Lei Hou, Hui Xiao, Xilong Gong, Xuhui Guo, Xuchen Cao, Zhenzhen Liu
Summary: This study identified differentially expressed genes in DCIS and normal tissue and validated a six-core gene signature with potential for prognostic prediction in DCIS.
Review
Endocrinology & Metabolism
Shelby Lynn Hophan, Olena Odnokoz, Huiping Liu, Yuan Luo, Seema Khan, William Gradishar, Zhuan Zhou, Sunil Badve, Mylin A. Torres, Yong Wan
Summary: Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer, but the molecular mechanisms behind its progression to invasive ductal carcinoma (IDC) and the complexity of each lesion are still unclear. Understanding the molecular features that lead to DCIS progression and finding new strategies to identify molecular mechanisms are crucial for more targeted therapy.
Article
Genetics & Heredity
Esther H. Lips, Tapsi Kumar, Anargyros Megalios, Lindy L. Visser, Michael Sheinman, Angelo Fortunato, Vandna Shah, Marlous Hoogstraat, Emi Sei, Diego Mallo, Maria Roman-Escorza, Ahmed A. Ahmed, Mingchu Xu, Alexandra W. Van den Belt-Dusebout, Wim Brugman, Anna K. Casasent, Karen Clements, Helen R. Davies, Liping Fu, Anita Grigoriadis, Timothy M. Hardman, Lorraine M. King, Marielle Krete, Petra Kristel, Michiel de Maaker, Carlo C. Maley, Jeffrey R. Marks, Brian A. Menegaz, Lennart Mulder, Frank Nieboer, Salpie Nowinski, Sarah Pinder, Jelmar Quist, Carolina Salinas-Souza, Michael Schaapveld, Marjanka K. Schmidt, Abeer M. Shaaban, Rana Shami, Mathini Sridharan, John Zhang, Hilary Stobart, Deborah Collyar, Serena Nik-Zainal, Lodewyk F. A. Wessels, E. Shelley Hwang, Nicholas E. Navin, P. Andrew Futreal, Alastair M. Thompson, Jelle Wesseling, Elinor J. Sawyer
Summary: A genomic analysis of ductal carcinoma in situ (DCIS) samples reveals that a significant portion of invasive breast cancer recurrences are unrelated to the initial DCIS and have distinct clonal origins. This finding is crucial for accurately assessing the risk of DCIS, developing effective treatment strategies, and identifying predictive biomarkers.
Article
Oncology
Gabriel Farante, Antonio Toesca, Francesca Magnoni, Germana Lissidini, Jose Vila, Mauro Mastropasqua, Giuseppe Viale, Silvia Penco, Enrico Cassano, Matteo Lazzeroni, Bernardo Bonanni, Maria Cristina Leonardi, Francisco Ripoll-Orts, Giuseppe Curigliano, Roberto Orecchia, Viviana Galimberti, Paolo Veronesi
Summary: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with heterogeneous pathological and biological traits. This article provides evidence-based guidelines for proper DCIS clinical management, emphasizing multidisciplinary team discussion and consideration of recent scientific studies. It also includes updated treatment protocols and techniques based on peer-reviewed medical literature and outlines future perspectives.
Article
Nutrition & Dietetics
Silvia D. Stan, Minna Abtahi
Summary: This study demonstrates that DATS inhibits cell proliferation and induces apoptosis in breast DCIS and minimally invasive breast cancer cells.
Article
Biochemistry & Molecular Biology
Joanna Szpor, Joanna Streb, Anna Glajcar, Anna Streb-Smolen, Agnieszka Lazarczyk, Paulina Korta, Karolina Brzuszkiewicz, Robert Jach, Diana Hodorowicz-Zaniewska
Summary: The density of dendritic cells (DCs) with different superficial antigens is associated with various histopathological characteristics of ductal carcinoma in situ (DCIS). CD123(+) and DC-LAMP(+) cells are correlated with tumor size, grading, and neoductgenesis, while CD1a(+) cells are negatively correlated with hormone receptor expression. Additionally, the number of DC-LAMP(+) cells is higher in DCIS with comedo necrosis, ductal spread, lobular cancerization, and comedo-type tumors, while CD1a(+) cells are abundant in cases with Paget disease. DC-LAMP seems particularly promising as a target for further research in this area.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Ying Jiang, Li Chai, Dandan Dong, Aamer Rasheed Chughtai, Weifang Kong
Summary: Mucocele-like tumors of the breast are associated with DCIS and have characteristic imaging features, with MR features not well-documented. FNAC carries a risk of tumor underestimation, so excision is recommended as the best approach, but close follow-up is suggested for low-risk patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Ruwangi Udayasiri, Tongtong Luo, Kylie L. Gorringe, Stephen B. Fox
Summary: Ductal carcinoma in situ (DCIS) is a non-invasive breast tumor with the potential to progress to invasive ductal carcinoma (IDC). The current inability to accurately predict the invasive potential of DCIS leads to both over-treatment and under-treatment in patients. Better understanding of the molecular features of DCIS could improve treatment decision-making and avoid unnecessary side-effects. This review summarizes the current knowledge of DCIS and discusses future research directions.
Article
Oncology
Rita Peila, Dorothy S. Lane, Aladdin H. Shadyab, Nazmus Saquib, Howard D. Strickler, JoAnn E. Manson, Kathy Pan, Thomas E. Rohan
Summary: This study found an inverse association between adopting a healthy lifestyle and the risk of DCIS, especially among women with a family history of breast cancer and ER+/PR+ DCIS.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Mathilde M. M. Almekinders, Michael Schaapveld, Bram Thijssen, Lindy L. Visser, Tycho Bismeijer, Joyce Sanders, Edoardo Isnaldi, Ingrid Hofland, Marjolijn Mertz, Lodewyk F. A. Wessels, Annegien Broeks, Erik Hooijberg, Wilbert Zwart, Esther H. Lips, Christine Desmedt, Jelle Wesseling
Summary: The study suggests that the size of breast adipocytes and COX-2 protein expression in DCIS cells are associated with the risk of subsequent invasive breast cancer. Large breast adipocytes and high COX-2 expression in DCIS are linked to a higher risk of developing invasive breast cancer.
Article
Oncology
Sunil S. Badve, Sanghee Cho, Xiaoyu Lu, Sha Cao, Soumya Ghose, Aye Aye Thike, Puay Hoon Tan, Idris Tolgay Ocal, Daniele Generali, Fabrizio Zanconati, Adrian L. Harris, Fiona Ginty, Yesim Gokmen-Polar
Summary: The study investigated the prognostic role of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) in multi-national cohorts from Asian and European women. It found that older women with circumferential TILs were less likely to develop second breast cancer events (BCE) at a 5-year follow-up. The spatial arrangement of TILs may serve as a better prognostic indicator in DCIS cases.
